Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in Illinois

The question keeps coming up: ‘Can I prescribe weight-loss medications as a psychiatrist or PMHNP?’ The short answer is yes — in most states, with the right training and compliance protocols. But the real answer is more nuanced, because state scope-of-practice laws, telehealth restrictions, and clinical competency requirements all come into play.

Here’s what you actually need to know about prescribing GLP-1 agonists (like Wegovy, Ozempic, Mounjaro) and other weight-loss medications as a psychiatric provider in 2026.

Why Psychiatrists Are Entering Weight Management

Let’s start with the clinical reality: many of your patients are struggling with obesity, often directly caused by the medications you prescribe. Atypical antipsychotics, mood stabilizers, certain antidepressants — these are weight-gain machines. You’re already monitoring metabolic labs, tracking BMI, counseling on lifestyle changes. So when a patient asks about semaglutide or phentermine, is that really outside your wheelhouse?

Not according to a growing number of psychiatrists who’ve added weight management to their scope. Dr. Elliott Lewis, a dual board-certified psychiatrist and obesity medicine specialist, puts it bluntly: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You’re already managing the metabolic fallout of psychiatric meds — why not treat it directly?

The Clinical Case for Psychiatric Providers Prescribing GLP-1s

GLP-1 receptor agonists aren’t just weight-loss drugs. Emerging evidence suggests they may have mental health benefits beyond metabolic improvement:

Reduced binge-eating impulses and food cravings in patients with eating disorders

Improved mood scores independent of weight loss in clinical trials (the STEP trials showed slightly lower rates of depressive symptoms in GLP-1 groups vs. placebo)

Potential neuroprotective effects — GLP-1s reduce systemic inflammation and may influence brain regions tied to reward and mood regulation

Lower substance use cravings — early research suggests GLP-1s might help with alcohol and nicotine dependence

The safety profile for mental health is reassuring. Despite early media panic about suicidality risk, a 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidal ideation with GLP-1 medications compared to placebo. FDA and EMA reviews confirmed no causal link.

For patients with psychiatric medication-induced weight gain, GLP-1 therapy can be part of comprehensive care — not a side gig, but an extension of treating the whole patient.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Legal Scope: Can You Prescribe Weight-Loss Meds?

Psychiatrists (MD/DO): Full Prescriptive Authority

If you’re a licensed physician, you have broad prescriptive authority in all 50 states for FDA-approved weight-loss medications:

GLP-1 agonists (semaglutide/Wegovy, liraglutide/Saxenda, tirzepatide) — non-controlled, can prescribe anywhere

Phentermine (Schedule IV) — legal in most states; some states restrict controlled substance prescribing via telehealth (more on that below)

Phentermine/topiramate (Qsymia) — combination therapy, controlled

Naltrexone/bupropion (Contrave) — non-controlled

Scope concerns? Addressed. Scope of practice isn’t defined by specialty title — it’s defined by competency and training. If you’ve gained expertise in obesity medicine (through CME, mentorship, or formal certification like the American Board of Obesity Medicine), prescribing these medications is within a reasonable scope. Many psychiatrists already manage general medical issues in practice (thyroid checks, hypertension from lithium, diabetes monitoring). Adding metabolic treatment for obesity is a logical extension, especially when it overlaps with psychiatric care.

One caveat: Some states impose specific clinical standards for weight-loss prescribing (see state-by-state details below). For example, Florida requires documented BMI thresholds, informed consent, and quarterly follow-ups for any obesity medication. You must follow those rules regardless of your specialty.

PMHNPs: It Depends on Your State

Nurse practitioners face a patchwork of state laws that determine whether you can prescribe weight-loss medications independently or need physician collaboration.

States with Full Practice Authority (FPA): In roughly 24 states + DC, experienced PMHNPs can prescribe independently without physician oversight. Examples include:

California (phased FPA via AB 890; full independence starting Jan 2026 for certified ‘104’ NPs)

New York (independent after 3,600 hours of practice)

Illinois (FPA after ≥4,000 hours + 250 CE hours; can prescribe controlled substances with some Schedule II caveats)

In these states, a PMHNP with FPA can legally prescribe GLP-1s and other weight-loss medications on their own authority — no physician signature required.

States Requiring Collaboration/Delegation: In ~26 states, PMHNPs must have a written collaborative or prescriptive authority agreement with a physician. Examples:

Texas — strict Prescriptive Authority Agreement (PAA) required; physician must sign off on protocols and conduct monthly chart reviews

Florida — APRNs must practice under physician protocol; autonomous practice exists for primary care NPs only, not PMHNPs, and excludes controlled substances

Pennsylvania — collaboration agreement required; physician name must appear on prescriptions alongside the NP’s

In collaboration states, you can prescribe weight-loss meds, but the supervising physician must delegate that authority in your agreement and be available for consultation. Some agreements explicitly list drug categories (e.g., ‘Schedule IV anorectics, GLP-1 agonists for obesity management’).

One practical barrier: Even in FPA states, some insurers and pharmacies hesitate to process GLP-1 prescriptions from NPs without physician involvement — not because it’s illegal, but because of internal policies around high-cost medications. This is less common now, but it’s something to anticipate. Having a collaborative physician (even in an FPA state) can smooth insurance credentialing and prior authorizations.

Specialty Scope Question: Does prescribing weight-loss medications fall within a psychiatric NP’s scope? It’s a gray area. Your training emphasizes mental health, not endocrinology. However, scope is about competency, not rigid specialty boxes. If you’re treating a patient with SSRI-induced weight gain or binge-eating disorder, adding a GLP-1 as part of holistic care is defensible. If you’re running a standalone weight-loss clinic with no psychiatric component, that’s riskier — state boards could argue you’re practicing outside your population focus. Best practice: Pursue additional training (obesity medicine CME, certification) and focus on patients where weight and mental health intersect.

State-Specific Rules You Can’t Ignore

Beyond general scope laws, several states impose clinical practice standards for weight-loss prescribing. Violating these can trigger board investigations regardless of your license type.

Florida: Strict Obesity Treatment Protocols

Florida’s Board of Medicine (rule 64B15-14.004) sets detailed requirements:

BMI criteria: Patients must have BMI ≥30, or ≥27 with a weight-related comorbidity (diabetes, hypertension, etc.) to qualify for anti-obesity medications

Initial evaluation: Comprehensive history and physical exam required before prescribing (can be conducted by an APRN/PA under delegation, but must be thorough)

Informed consent: Written consent discussing risks, benefits, alternatives — documented in the chart

Patient education: Must provide Florida’s ‘Weight-Loss Consumer Bill of Rights’ brochure

Follow-up: Face-to-face visit (telehealth counts) at least every 3 months while on medication; failure to monitor quarterly is a violation

Labs and workup: Rule out secondary causes of obesity (thyroid, Cushing’s, etc.) before prescribing

Telehealth caveat: Florida law prohibits prescribing controlled substances via telehealth for most indications. Weight loss is not an exception. That means you cannot prescribe phentermine (Schedule IV) via telehealth to Florida patients under current state law — even though federal DEA waivers allow it. GLP-1s (non-controlled) are fine via telehealth as long as you meet the clinical standards above.

Enforcement: Florida aggressively disciplines providers for lax obesity treatment practices. Clinics have been cited for skipping follow-ups, treating low-BMI patients, or failing to document informed consent. Take these rules seriously.

Texas: Delegation and Chart Review Requirements

NPs must have a Prescriptive Authority Agreement explicitly authorizing weight-loss medications (list drug categories like ‘Schedule IV anorectics, GLP-1 agonists’)

Monthly physician meetings required for quality assurance

No Schedule II stimulants for weight loss (state law bans amphetamines for obesity; phentermine is Schedule IV, so it’s allowed)

PMP checks: Texas requires checking the Prescription Monitoring Program for controlled substances

Telehealth: Allowed for weight-loss treatment; standard of care applies (document exam, rationale)

Corporate Practice of Medicine: Texas enforces strict CPM rules — only physicians can make medical decisions. NP-run telehealth weight-loss companies must structure as physician-owned or use MSO models.

New York: Minimal State Rules, Maximum Physician Flexibility

New York doesn’t impose specific obesity prescribing regulations beyond standard medical practice. Key points:

NP independence: After 3,600 hours of practice, PMHNPs can prescribe without a collaborating physician

Controlled substances: Must check the I-STOP PMP before prescribing any Schedule II-IV drug (including phentermine)

Telehealth: Fully supported; payment parity law in effect (commercial insurers must reimburse telehealth visits equally)

No geographic restrictions on telehealth psychiatric care

New York expects you to follow national clinical guidelines (Endocrine Society, Obesity Medicine Association) even without state-specific rules. Document BMI, comorbidities, lifestyle counseling, and monitoring plans.

California: FPA Phasing In, CPOM Still a Factor

AB 890 independence: NPs completing a 3-year/4,600-hour transition under physician supervision can practice independently starting Jan 1, 2026 (for ‘104’ NPs). During transition, physician protocols required.

Controlled substances: Even independent NPs cannot prescribe Schedule II-V drugs for weight loss yet — you need to complete the AB 890 pathway to gain independent furnishing privileges

Corporate Practice of Medicine: Only MDs can own medical practices. NPs (even with FPA) must operate within physician-owned structures or use MSO models for telehealth businesses

Telehealth: No state restrictions; payment parity enforced

Practical tip: Most California telehealth weight-loss companies use physician medical directors to navigate CPOM and ensure controlled substance prescribing authority.

Illinois: FPA Available, Schedule II Nuances

Full Practice Authority: PMHNPs with ≥4,000 hours + 250 CE hours can prescribe independently, including controlled substances

Schedule II caveats: For the first year of Schedule II prescribing, you need a physician consultation relationship (mainly relevant for ADHD stimulants, not typical weight-loss meds)

Medicaid reimbursement: Illinois pays APRNs at 100% of physician rates — a strong financial incentive

Telehealth: Broad parity laws; no extra restrictions

Pennsylvania: Collaboration Required, No FPA Yet

All PMHNPs must have a collaboration agreement with a physician; physician’s name appears on prescriptions

Prescriptive authority: Delegated via the agreement; physician must review charts regularly

No special obesity rules at state level; follow best practices

Telehealth: Permitted; limited parity (mental health covered at par via Act 69, but not all services yet)

Mississippi and Other Outliers: Off-Label GLP-1 Ban

Mississippi’s Board of Medical Licensure banned off-label prescribing of GLP-1 agonists solely for weight loss in August 2023. You must use FDA-approved obesity formulations (Wegovy, not Ozempic) unless treating diabetes. Other states haven’t gone this far, but it highlights increasing scrutiny.

Telehealth Prescribing: Federal vs. State Rules

This is where providers get tripped up. Federal law (DEA) allows controlled substance prescribing via telehealth through Dec 31, 2025 (likely extended into 2026) without a prior in-person exam. But state laws can override federal flexibility.

States That Prohibit or Restrict Telehealth Controlled Substance Prescribing:

Florida: No controlled substance prescribing via telehealth except for psychiatric disorders, inpatient/hospice care, or acute pain. Weight loss doesn’t qualify. You cannot prescribe phentermine via telehealth in Florida.

Alabama: Requires initial in-person exam for controlled substances (no purely remote start for phentermine)

Idaho, South Carolina: Have similar in-person requirements for controlled drugs

For GLP-1s (non-controlled): No telehealth restrictions in any state, as long as you meet standard-of-care requirements (thorough evaluation, monitoring plan, documentation).

Best practice: Use video visits for initial consultations. Some providers tried asynchronous (questionnaire-only) prescribing and faced discipline. In May 2023, a Mississippi doctor’s license was suspended for prescribing Ozempic via instant messaging with no video exam. The board deemed it inadequate for establishing a patient relationship.

Reimbursement: Is Weight Management Financially Viable?

Insurance Coverage for GLP-1s: Improving Rapidly

Commercial insurance: Most major insurers now cover FDA-approved weight-loss GLP-1s (Wegovy, Saxenda) with prior authorization. Expect to document:

BMI ≥30 (or ≥27 with comorbidity)

Evidence of lifestyle modification attempts (diet, exercise)

Comprehensive weight management plan (not just pills)

Medicare: Starting 2026, Medicare will cover anti-obesity medications for the first time — a game-changer for seniors. Expect Medicare Part D formularies to add Wegovy, Mounjaro once final rules publish.

Medicaid: State-by-state; some states already cover GLP-1s for obesity, others are expanding coverage following Medicare’s lead.

Prior authorization tips: Be prepared to fill out detailed PA forms. Some insurers impose 30-day supply limits initially to monitor adherence and side effects before approving refills.

Billing for Weight Management Visits

Psychiatrists (MD/DO): Use standard E/M codes (99213-99215 for established patients) or psychiatric evaluation codes (90792 for initial, 90833/90836 if combined with therapy). Reimbursement: ~$75-$200 depending on complexity and region. Medicare pays 100% of physician fee schedule.

PMHNPs: Typically reimbursed at 85% of physician rates by Medicare; some private insurers pay 85-100%. Illinois Medicaid pays NPs at 100% of physician rates.

Telehealth parity: California, New York, Illinois, and Pennsylvania have laws requiring equal payment for telehealth vs. in-person visits (at least for mental health services). Medicare extended telehealth parity for psychiatric services through at least 2025.

Coding tip: Use obesity diagnosis codes (E66.x) as primary when the visit focuses on weight management. Add the telehealth modifier (95 or GT) or POS 02 for proper reimbursement.

Cash-Pay vs. Insurance: What Works?

Many early telehealth weight-loss companies went cash-pay (monthly subscriptions, per-visit fees) because insurance was a hassle. But as coverage expands, insurance-based models are becoming more attractive — patients can afford $1,300/month GLP-1s if insurance covers them, whereas cash-pay limits you to affluent patients.

For Klarity providers: The platform handles insurance billing and patient matching, so you don’t waste time on prior auths or claims denials. You see pre-qualified patients, provide care, and get paid per appointment. No marketing spend, no rejected claims eating into your revenue.

How to Start Prescribing Weight-Loss Medications Competently

If you’re ready to add weight management to your practice, here’s the roadmap:

1. Get Trained

   Don’t wing it. Obesity medicine has nuances (drug interactions, contraindications, monitoring protocols) you didn’t learn in psychiatry residency. Options:

CME courses in obesity treatment (60+ hours available through Obesity Medicine Association)

American Board of Obesity Medicine (ABOM) certification — open to physicians of any specialty; requires education + exam. Demonstrates formal competency and addresses scope concerns directly.

Mentorship — shadow an endocrinologist or obesity specialist for a few months

2. Know Your State’s Rules

Review the specific requirements in your state (see table above). If you’re in Florida, Texas, or another high-regulation state, build protocols for:

BMI documentation

Informed consent forms

Quarterly follow-up scheduling

PMP checks (for controlled substances)

Lab ordering (thyroid, glucose, lipids)

3. Integrate Into Psychiatric Care

The strongest clinical and legal justification for psychiatric providers prescribing weight-loss meds is treating patients where obesity and mental health overlap. Examples:

Patient on olanzapine who gained 40 lbs → add metformin or semaglutide

Patient with binge-eating disorder + depression → GLP-1 + therapy

ADHD patient with metabolic syndrome → structured treatment plan addressing both

This isn’t ‘expanding scope to grab more patients’ — it’s comprehensive care for the patients you already see.

4. Collaborate (Even If Not Required)

Even in FPA states, having a physician collaborator with obesity medicine expertise strengthens your practice:

Provides consultation for complex cases

Smooths insurance credentialing

Protects you legally if a complication arises

In collaboration-required states, choose a physician who actually understands weight management, not just someone signing off for a fee.

5. Document Everything

Weight-loss prescribing is scrutinized. Your chart should include:

Current BMI and qualifying comorbidities

Discussion of risks, benefits, alternatives

Lifestyle modification plan (diet, exercise referrals)

Monitoring schedule (follow-up dates)

For controlled substances: PMP check documentation

Why this matters: State boards investigate providers for ‘pill mill’ practices. Thorough documentation proves you’re practicing competently, not just rubber-stamping prescriptions.

FAQ: Weight-Loss Prescribing for Psychiatric Providers

Can a psychiatrist prescribe Wegovy or Ozempic?

Yes. Psychiatrists (MD/DO) can prescribe any FDA-approved weight-loss medication, including GLP-1 agonists, in all 50 states. Some states require you to follow specific clinical protocols (like Florida’s BMI thresholds and quarterly follow-ups), but there’s no law prohibiting psychiatrists from treating obesity.

Can a PMHNP prescribe weight-loss medications independently?

It depends on your state. In full practice authority states (California starting 2026, New York after 3,600 hours, Illinois with FPA status), yes. In collaboration states (Texas, Florida, Pennsylvania), you need a physician’s delegation. Even in FPA states, some insurers may require physician involvement for high-cost GLP-1 prescriptions.

Is prescribing GLP-1s outside a psychiatric NP’s scope of practice?

Not necessarily. Scope is about competency, not specialty title. If you’ve gained training in obesity medicine and you’re treating patients where weight and mental health intersect (e.g., antipsychotic-induced weight gain), it’s defensible. If you’re running a standalone weight-loss clinic with no psychiatric component, that’s riskier — consider additional certification or collaboration.

Can I prescribe phentermine via telehealth?

Federally, yes (through at least Dec 31, 2025, likely extended). But state law varies:

Florida: No — controlled substances cannot be prescribed via telehealth for weight loss

Alabama: No — requires initial in-person exam

Texas, New York, California, Illinois, Pennsylvania: Yes, as long as you follow standard-of-care requirements (thorough telehealth evaluation, PMP check, documentation)

What are the risks of prescribing GLP-1s to psychiatric patients?

Minimal mental health risk. Meta-analyses show no increase in depression or suicidality with GLP-1s. Some patients report improved mood. Main risks are GI side effects (nausea, vomiting), potential gallbladder issues, and rare cases of pancreatitis. Screen for contraindications (history of medullary thyroid cancer, MEN2 syndrome). Monitor closely if patient has a history of eating disorders (GLP-1s suppress appetite, which could complicate recovery).

Do I need malpractice insurance that covers weight-loss prescribing?

Yes. Check with your carrier. Most psychiatrist malpractice policies cover weight management as long as it’s within your scope and you’re trained. If you’re adding a significant weight-loss service line, disclose it to your insurer to avoid coverage gaps.

How do I bill insurance for weight management visits?

Use standard E/M codes (99213-99215) or psychiatric evaluation codes (90792, 90833/90836). Use obesity diagnosis codes (E66.x) as primary. For Medicare patients, you can also use G0447 (obesity counseling) if providing behavioral counseling, though most psychiatrists stick with E/M codes. Add telehealth modifiers (95, GT, or POS 02) for remote visits.

Why Klarity Makes Sense for Providers Entering Weight Management

Here’s the reality of launching a weight-loss service line on your own:

DIY marketing (SEO, Google Ads, directory listings) costs $200-500+ per acquired patient when you factor in ad spend, agency fees, staff time, no-shows, and failed campaigns. SEO takes 6-12 months before generating meaningful patient flow. Google Ads for ‘weight loss doctor’ cost $15-40+ per click, and most clicks don’t convert.

Collaborative physician fees (if required in your state): $2,000-5,000/month for a medical director, plus chart review time.

Insurance credentialing and billing: 3-6 months to get paneled, then ongoing denials, prior auth requests, claim resubmissions.

Telehealth platform and EHR: $100-500/month for software that handles video visits, prescribing, and compliance.

Total upfront cost to launch a telehealth weight-loss practice independently: $5,000-10,000+ before you see a single patient. And you’re gambling that your marketing will work.

Klarity’s model removes the risk:

No upfront marketing spend. You pay a standard listing fee per new patient lead — only when you see patients.

Pre-qualified patients already matched to your specialty and availability. No wasted ad spend on clicks that don’t convert.

Built-in telehealth infrastructure. EHR, video platform, prescribing tools included.

Insurance and cash-pay patient flow. Klarity handles billing and credentialing.

You control your schedule. Take as many or as few patients as you want; scale up without hiring a marketing agency.

Economics: Instead of spending $3,000-5,000/month on marketing with uncertain ROI, you pay only when you generate revenue (seeing a patient). That’s guaranteed ROI, not a gamble.

For providers just starting in weight management or those scaling an existing practice, Klarity eliminates the patient acquisition problem entirely. You focus on clinical care; Klarity handles the rest.

The Bottom Line

Can you prescribe weight-loss medications as a psychiatrist or PMHNP? Yes — with the right training, state compliance, and clinical rationale.

Should you? If you’re already managing patients with metabolic issues, medication-induced weight gain, or co-occurring obesity and mental health conditions, adding GLP-1s and other weight-loss treatments is a natural extension of comprehensive care.

The regulatory landscape is complex, but navigable. Know your state’s scope laws, follow clinical protocols, document thoroughly, and consider formal training (ABOM certification, obesity medicine CME) to solidify your competency.

And if you want to add weight management without the headache of patient acquisition, marketing spend, and billing nightmares — join a platform that handles the business side so you can focus on treating patients.

Ready to explore joining Klarity’s provider network? We match you with pre-qualified patients seeking psychiatric and metabolic care via telehealth, handle insurance billing, and provide the infrastructure you need to scale without the upfront risk. Learn more about becoming a Klarity provider.

Sources and References

MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ – Industry analysis on NP scope and collaboration requirements across states. Updated 2025. www.medicaldirectorco.com

Florida Administrative Code Rule 64B15-14.004 – Standards for Prescription of Obesity Drugs – Official state regulation detailing BMI criteria, informed consent, follow-up requirements for Florida providers. Effective Aug 8, 2022. www.law.cornell.edu

MedicalDirector Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ – Comprehensive state-specific legal summary covering APRN collaboration, clinic licensing, telehealth restrictions. Updated 2025. www.medicaldirectorco.com

MedicalDirector Co. – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ – Overview of Texas prescriptive authority agreements, corporate practice of medicine, telehealth standards. Updated 2025. www.medicaldirectorco.com

The Nurse Practitioner Journal (Susanne J. Phillips) – ’36th Annual APRN Legislative Update: Improving Access to Care and Removing Barriers to Practice’ – Peer-reviewed state-by-state summary of NP scope laws, including New York’s NP Modernization Act, Illinois FPA, Pennsylvania collaboration requirements, California AB 890 implementation. January 2024. journals.lww.com

Foley & Lardner (Mondaq) – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ – Legal analysis covering state board rules (New Jersey, Virginia, Mississippi GLP-1 ban), compounded semaglutide warnings, insurance coverage trends. July 2023. www.mondaq.com

RxAgent.co (Samuel Stolting, PharmD) – ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ – Analysis of state telehealth prescribing restrictions vs. federal DEA waivers; identifies Florida, Alabama, and other states banning controlled substance telehealth for weight loss. Dec 16, 2025. rxagent.co

Dr. Elliott Lewis, MD – ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective’ – Psychiatrist’s clinical perspective on scope, training (ABOM certification), and integration of obesity treatment into psychiatric practice. Jan 4, 2026. drlewis.com

Dr. Elliott Lewis, MD – ‘GLP-1 Medications & Mental Health: Facts vs Myths’ – Evidence review on GLP-1 safety (no suicidality risk), potential mental health benefits, and metabolic-psychiatric care integration. Nov 26, 2025. drlewis.com

Axios Health News – ‘COVID-era telehealth prescribing extended again’ – News confirming DEA’s Fourth Extension of telehealth controlled substance prescribing waivers through Dec 31, 2025. Nov 18, 2024. axios.com

Axios – ‘Trump announces Medicare coverage of weight-loss drugs’ – Report on Medicare policy shift to cover anti-obesity medications starting 2026. Nov 6, 2025. axios.com

TheraThink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ – Billing guide with CPT code reimbursement rates for psychiatric services (E/M, med management). Updated 2026. therathink.com

Blue Cross Blue Shield of Texas – Provider Notice: ‘Pharmacy Supply Limit for GLP-1 Medications for Obesity’ – Insurer bulletin on 30-day supply limits for new GLP-1 prescriptions. Oct 4, 2024. bcbstx.com

This content is for informational purposes only and does not constitute legal or medical advice. Consult your state’s medical board, nursing board, and legal counsel for specific regulatory guidance. Laws and regulations change frequently; verify current requirements before implementing any practice changes.

Source:

https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes

https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20

https://journals.lww.com/tnpj/fulltext/2024/01000/36th annualaprn legislativeupdate__improving.6.aspx#::text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare

https://journals.lww.com/tnpj/fulltext/2024/01000/36th annualaprn legislativeupdate__improving.6.aspx#:

https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level

https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers

https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants

https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated

https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself

https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting